INTRODUCTION: The postoperative seizure freedom represents an important secondary outcome measure in glioblastoma surgery. Recently, supra-total glioblastoma resection in terms of anterior temporal lobectomy (ATL) has gained growing attention with regard to superior long-term disease control for temporal-located glioblastoma compared to conventional gross-total resections (GTR). However, the impact of ATL on seizure outcome in these patients is unknown. We therefore analyzed ATL and GTR as differing extents of resection in regard of postoperative seizure control in patients with temporal glioblastoma and preoperative symptomatic seizures. METHODS: Between 2012 and 2018, 33 patients with preoperative seizures underwent GTR or ATL for temporal glioblastoma at the authors' institution. Seizure outcome was assessed postoperatively and 6 months after tumor resection according to the International League Against Epilepsy (ILAE) classification and stratified into favorable (ILAE class 1) versus unfavorable (ILAE class 2-6). RESULTS: Overall, 23 out of 33 patients (70%) with preoperative seizures achieved favorable seizure outcome following resection of temporal located glioblastoma. For the ATL group, postoperative seizure freedom was present in 13 out of 13 patients (100%). In comparison, respective rates for the GTR group were 10 out of 20 patients (50%) (p = 0.002; OR 27; 95% CI 1.4-515.9). CONCLUSIONS: ATL in terms of a supra-total resection strategy was associated with superior favorable seizure outcome following temporal glioblastoma resection compared to GTR. Regarding above mentioned survival benefit following ATL compared to GTR, ATL as an aggressive supra-total resection regime might constitute the surgical modality of choice for temporal-located glioblastoma.
INTRODUCTION: The postoperative seizure freedom represents an important secondary outcome measure in glioblastoma surgery. Recently, supra-total glioblastoma resection in terms of anterior temporal lobectomy (ATL) has gained growing attention with regard to superior long-term disease control for temporal-located glioblastoma compared to conventional gross-total resections (GTR). However, the impact of ATL on seizure outcome in these patients is unknown. We therefore analyzed ATL and GTR as differing extents of resection in regard of postoperative seizure control in patients with temporal glioblastoma and preoperative symptomatic seizures. METHODS: Between 2012 and 2018, 33 patients with preoperative seizures underwent GTR or ATL for temporal glioblastoma at the authors' institution. Seizure outcome was assessed postoperatively and 6 months after tumor resection according to the International League Against Epilepsy (ILAE) classification and stratified into favorable (ILAE class 1) versus unfavorable (ILAE class 2-6). RESULTS: Overall, 23 out of 33 patients (70%) with preoperative seizures achieved favorable seizure outcome following resection of temporal located glioblastoma. For the ATL group, postoperative seizure freedom was present in 13 out of 13 patients (100%). In comparison, respective rates for the GTR group were 10 out of 20 patients (50%) (p = 0.002; OR 27; 95% CI 1.4-515.9). CONCLUSIONS: ATL in terms of a supra-total resection strategy was associated with superior favorable seizure outcome following temporal glioblastoma resection compared to GTR. Regarding above mentioned survival benefit following ATL compared to GTR, ATL as an aggressive supra-total resection regime might constitute the surgical modality of choice for temporal-located glioblastoma.
Authors: Matthias Preusser; Sandrine de Ribaupierre; Adelheid Wöhrer; Sara C Erridge; Monika Hegi; Michael Weller; Roger Stupp Journal: Ann Neurol Date: 2011-07 Impact factor: 10.422
Authors: Ulrich Herrlinger; Theophilos Tzaridis; Frederic Mack; Joachim Peter Steinbach; Uwe Schlegel; Michael Sabel; Peter Hau; Rolf-Dieter Kortmann; Dietmar Krex; Oliver Grauer; Roland Goldbrunner; Oliver Schnell; Oliver Bähr; Martin Uhl; Clemens Seidel; Ghazaleh Tabatabai; Thomas Kowalski; Florian Ringel; Friederike Schmidt-Graf; Bogdana Suchorska; Stefanie Brehmer; Astrid Weyerbrock; Miriam Renovanz; Lars Bullinger; Norbert Galldiks; Peter Vajkoczy; Martin Misch; Hartmut Vatter; Moritz Stuplich; Niklas Schäfer; Sied Kebir; Johannes Weller; Christina Schaub; Walter Stummer; Jörg-Christian Tonn; Matthias Simon; Vera C Keil; Michael Nelles; Horst Urbach; Martin Coenen; Wolfgang Wick; Michael Weller; Rolf Fimmers; Matthias Schmid; Elke Hattingen; Torsten Pietsch; Christoph Coch; Martin Glas Journal: Lancet Date: 2019-02-14 Impact factor: 79.321
Authors: Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce Journal: Nat Med Date: 2013-09-22 Impact factor: 53.440
Authors: Timothy J Brown; Matthew C Brennan; Michael Li; Ephraim W Church; Nicholas J Brandmeir; Kevin L Rakszawski; Akshal S Patel; Elias B Rizk; Dima Suki; Raymond Sawaya; Michael Glantz Journal: JAMA Oncol Date: 2016-11-01 Impact factor: 31.777